Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Market Closed 12-20 16:00:00 EST

15.48

+0.64

+4.31%

盘后15.48

+0.000.00%

16:13 EST

High15.80	Low14.61	Vol812.20K
Open14.70	D1 Closing14.84	Amplitude8.02%
Mkt Cap419.31M	Tradable Cap383.92M	Total Shares27.09M
T/O12.54M	T/O Rate3.27%	Tradable Shares24.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":15.48,"timestamp":1734728400000,"preClose":14.84,"halted":0,"volume":812195,"hourTrading":{"tag":"盘后","latestPrice":15.48,"preClose":15.48,"latestTime":"16:13 EST","volume":204044,"amount":3158601.01,"timestamp":1734729216034},"delay":0,"floatShares":24801158,"shares":27087359,"eps":-2.329253,"marketStatus":"Market Closed","change":0.64,"latestTime":"12-20 16:00:00 EST","open":14.7,"high":15.8,"low":14.61,"amount":12537603.5509,"amplitude":0.080189,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.329253,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":14.84,"preHourTrading":{"tag":"盘前","latestPrice":15,"preClose":14.84,"latestTime":"09:20 EST","volume":718,"amount":10705.188294,"timestamp":1734704422580},"postHourTrading":{"tag":"盘后","latestPrice":15.48,"preClose":15.48,"latestTime":"16:13 EST","volume":204044,"amount":3158601.01,"timestamp":1734729216034},"volumeRatio":1.7078922684832631,"impliedVol":0.4183,"impliedVolPercentile":0.0159},"requestUrl":"/m/hq/s/ARCT/wiki","defaultTab":"wiki","newsList":[{"id":"2492541158","title":"We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2492541158","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492541158?lang=en_us&edition=fundamental","pubTime":"2024-12-20 19:34","pubTimestamp":1734694462,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So, the natural question for Arcturus Therapeutics Holdings  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.View our latest analysis for Arcturus Therapeutics Holdings. Arcturus Therapeutics Holdings has a market capitalisation of US$401m and burnt through US$62m last year, which is 15% of the company's market value. As a result, we'd","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-not-very-worried-arcturus-113422246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","TQQQ",".IXIC","BK4139","USJW.SI","NDAQ","QID","NVIW.SI","NQmain","BK4112","IE00B3QW5Z07.USD","MNQmain","USAW.SI","LU2210149790.SGD","LU2095319765.USD","PSQ","QLD","TSYW.SI","BK4585","BK4588","ARCT"],"gpt_icon":1},{"id":"2492692497","title":"Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492692497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492692497?lang=en_us&edition=fundamental","pubTime":"2024-12-18 13:50","pubTimestamp":1734501010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) and M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arcturus-therapeutics-arct-and-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arcturus-therapeutics-arct-and-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","ARCT","MDGL","BK4137","HCSG","BK4588"],"gpt_icon":0},{"id":"2490486016","title":"Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers","url":"https://stock-news.laohu8.com/highlight/detail?id=2490486016","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490486016?lang=en_us&edition=fundamental","pubTime":"2024-12-12 00:55","pubTimestamp":1733936108,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc.  stands against other worst ARK stocks to buy according to short sellers.Cathie Wood ofARK Investmentis one of Wall Street’s most well-known hedge fund bosses. In a hedge fund industry dominated by players that focus on quantitative trading, value stocks, and balanced portfolios, Wood stands out from the pack by focusing on disruptive innovation and firms that she and her firm believe will change the world.At the heart of Ark Invest’s trading strategy is the fund’s flagship ARK Innovation ETF fund. Over the past five years, this fund has gained a modest 23% which is substantially lower than the flagship S&P index’s 93.5%. Zooming into its 2024 performance, this fund has gained 20.5% while the index is up by 28.3%.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5wptGPpITOozMDVUNSZx9Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d27550770a7f77135d3a5312616d88a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5wptGPpITOozMDVUNSZx9Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d27550770a7f77135d3a5312616d88a0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-arcturus-therapeutics-arct-worst-165508619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BK4139","PSQ","ARKK","QLD","BK4588","BK4585","NQmain","BK4544","TQQQ","ARCT","SQQQ","QID",".IXIC"],"gpt_icon":1},{"id":"2486834298","title":"Arcturus Therapeutics to Attend Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2486834298","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486834298?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:01","pubTimestamp":1732654860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, November 26, 2024----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:. Webcast links can be found under Investor Relations/Events section of Arcturus’ website.Arcturus Therapeutics Public Relations & Investor RelationsNeda SafarzadehVP, Head of IR/PR/Marketing 900-2682IR@ArcturusRx.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5hl.D4MLnMOD1sOo855LHw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d3d6d783d9dbc0ba3096aa4405dbfebd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5hl.D4MLnMOD1sOo855LHw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d3d6d783d9dbc0ba3096aa4405dbfebd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-attend-upcoming-investor-210100323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4505","ARCT","BK4139","LENZ","RNA","BK4093","CF","BK4588"],"gpt_icon":0},{"id":"2484322639","title":"Arcturus Therapeutics to Present at Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2484322639","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484322639?lang=en_us&edition=fundamental","pubTime":"2024-11-19 09:00","pubTimestamp":1731978000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, November 19, 2024----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT.Arcturus TherapeuticsPublic Relations & Investor RelationsNeda SafarzadehVP, Head of Investor Relations/PR & Marketing 900-2682IR@ArcturusRx.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ayEV.42liLzOxEkKDS7rkQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/5d70676411f8e76fdafb7bfbe3001f8f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ayEV.42liLzOxEkKDS7rkQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/5d70676411f8e76fdafb7bfbe3001f8f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-present-jefferies-london-010000794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","RNA","BK4505","BK4093","CF","BK4585","ARCT","BK4137","LENZ","BK4139","BK4588"],"gpt_icon":0},{"id":"2483819575","title":"Meiji Seika Pharma Announces Investment in Arcalis, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483819575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483819575?lang=en_us&edition=fundamental","pubTime":"2024-11-14 14:00","pubTimestamp":1731564001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA6SGVYS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2483848308","title":"Meiji Seika Pharma Announces Investment in ARCALIS, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483848308","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483848308?lang=en_us&edition=fundamental","pubTime":"2024-11-14 14:00","pubTimestamp":1731564000,"startTime":"0","endTime":"0","summary":"TOKYO, November 14, 2024----Meiji Seika Pharma Co., Ltd.  today announced its investment in ARCALIS, Inc. .ARCALIS is a joint venture between Axcelead, Inc., which manages a group of world-class pharmaceutical and healthcare platform companies, and Arcturus Therapeutics, Inc. a commercial mRNA medicines and vaccines company. ARCALIS is engaged in the development of mRNA pharmaceuticals and vaccines, as well as contract development and manufacturing organization  services. The company plans to establish a comprehensive system for the domestic production of mRNA vaccines, ranging from the development of manufacturing technologies to the production of both active pharmaceutical ingredients and formulations.In response to the lessons learned from the delays experienced in the development of COVID-19 vaccines during the pandemic, ARCALIS and Meiji Seika Pharma are committed to advancing the development, production, and supply of mRNA vaccines in line with the \"Strategy for Strengthening Vac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiji-seika-pharma-announces-investment-060000101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT","CDMO","BK4139"],"gpt_icon":0},{"id":"2482949764","title":"Arcturus Therapeutics Gets FDA Greenlight for H5N1 Pandemic Flu Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482949764","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482949764?lang=en_us&edition=fundamental","pubTime":"2024-11-12 06:19","pubTimestamp":1731363556,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  said late Monday the US Food and Drug Administration has given the clearance to begin the clinical study for its H5N1 pandemic flu vaccine candidate ARCT-2304.The company said the trial, which is funded by the Biomedical Advanced Research and Development Authority, is designed to enroll around 200 healthy adults in the US.The phase 1 trial aims to evaluate the safety, reactogenicity, and immunogenicity of the \"self-amplifying\" mRNA vaccine, Arctus said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ARCT","LENZ"],"gpt_icon":0},{"id":"2482976564","title":"BRIEF-Arcturus Therapeutics Receives Clearance From FDA To Begin H5N1 Pandemic Flu Vaccine Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482976564","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482976564?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:10","pubTimestamp":1731359453,"startTime":"0","endTime":"0","summary":"Nov 11  - Arcturus Therapeutics Holdings Inc :   * ARCTURUS THERAPEUTICS RECEIVES CLEARANCE FROM FDA TO BEGIN H5N1 PANDEMIC FLU VACCINE CLINICAL TRIAL   * ARCTURUS THERAPEUTICS HOLDINGS INC - STUDY TO ENROLL APPROXIMATELY 200 HEALTHY ADULTS IN U.S.Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","LENZ","BK4139"],"gpt_icon":0},{"id":"2482655747","title":"Arcturus Therapeutics receives FDA clearance to begin H5N1 vaccine trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482655747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482655747?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359114,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (ARCT) Holdings announced that the U.S. Food and Drug Administration has issued a “Study Can Proceed” notification for the Co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-receives-fda-clearance-to-begin-h5n1-vaccine-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcturus-therapeutics-receives-fda-clearance-to-begin-h5n1-vaccine-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARCT","LENZ"],"gpt_icon":0},{"id":"2482763426","title":"Arcturus Therapeutics Holdings Inc - Study to Enroll Approximately 200 Healthy Adults in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482763426","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482763426?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA1CZGQH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2482763102","title":"Arcturus Therapeutics Receives Clearance From FDA to Begin H5n1 Pandemic Flu Vaccine Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482763102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482763102?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA1CZGQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARCT"],"gpt_icon":0},{"id":"2482176340","title":"Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482176340","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482176340?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, November 11, 2024----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration  has issued a \"Study Can Proceed\" notification for the Company’s Investigational New Drug  application, ARCT-2304, a self-amplifying mRNA  vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The clinical study is funded by Biomedical Advanced Research and Development Authority  and designed to enroll approximately 200 healthy adults in the United States.\"Arcturus is actively engaged with the U.S. government to prepare for the next pandemic, and clearance to proceed into the clinic with our STARR self-amplifying mRNA technology is a key step in this important process,\" said Joseph Payne, President & CEO of Arcturus Therapeutics. \"The Phase 1 clinica","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b9MIr0q.Pd.0RO.DQOFHZg--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/8baeb7084ab68f4b81e10dd0badd3e6b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b9MIr0q.Pd.0RO.DQOFHZg--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/8baeb7084ab68f4b81e10dd0badd3e6b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-receives-clearance-fda-210100627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","HA","NA","RNA","BK4093","BK4139","BK4008","LENZ","BK4500","BK4505","ARCT","BK4141","BK4585","CF"],"gpt_icon":0},{"id":"1139087555","title":"Stock Track | Arcturus Therapeutics Soars on Strong Q3 Results, Promising mRNA Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1139087555","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139087555?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:40","pubTimestamp":1731336017,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Ltd.  saw its shares surge 5.13% on November 11th, driven by the company's impressive third-quarter financial results and updates on its promising mRNA pipeline.For the quarter, Arcturus Therapeutics reported better-than-expected revenue and earnings, demonstrating the company's progress in leveraging the potential of mRNA technology. The strong financial performance boosted investor confidence in the company's growth prospects.Additionally, Arcturus Therapeutics highlighte","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Arcturus Therapeutics Soars on Strong Q3 Results, Promising mRNA Pipeline","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ARCT"],"gpt_icon":0},{"id":"2482024442","title":"Arcturus Therapeutics (ARCT): Impressive Pipeline and Potentially Promising Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2482024442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482024442?lang=en_us&edition=fundamental","pubTime":"2024-11-11 19:23","pubTimestamp":1731324191,"startTime":"0","endTime":"0","summary":"With top-and-bottom-line beats for the most recent quarter, Arcturus Therapeutics ($ARCT) is making progress in unleashing the power of mRNA to rev...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/arcturus-therapeutics-arct-impressive-pipeline-and-potentially-promising-future?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/arcturus-therapeutics-arct-impressive-pipeline-and-potentially-promising-future?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARCT","BK4139"],"gpt_icon":0},{"id":"2482315429","title":"Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482315429","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482315429?lang=en_us&edition=fundamental","pubTime":"2024-11-09 22:25","pubTimestamp":1731162332,"startTime":"0","endTime":"0","summary":"NasdaqGM:ARCT Earnings and Revenue Growth November 9th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 14%. Earnings per share  also surpassed analyst estimates by 77%.Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are up 9.0% from a week ago.While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Arcturus Therapeutics Holdings' balance sheet.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-holdings-third-quarter-142532243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","ARCT"],"gpt_icon":0},{"id":"2482045487","title":"Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2482045487","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482045487?lang=en_us&edition=fundamental","pubTime":"2024-11-09 01:15","pubTimestamp":1731086105,"startTime":"0","endTime":"0","summary":"Neda Safarzadeh; Vice President - Head of Investor Relations, Public Relations and Marketing; Arcturus Therapeutics Holdings Inc. Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc. Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc. Padmanabh Chivukula; Chief Operating Officer, Chief Scientific Officer; Arcturus Therapeutics Holdings Inc. Thank you, Neda. It's good to be with you again everybody. We look forward to providing our updates today on our quarterly investor call. I will begin my remarks with an update on progress with our vaccine franchise led by KOSTAIVE, our self-amplifying mRNA COVID-19 vaccine. We're thrilled about our recent commercial launch of KOSTAIVE in Japan. Last month, members of our senior management team including myself had the wonderful opportunity to travel to Ja","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q3-2024-arcturus-therapeutics-holdings-171505971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT","LENZ"],"gpt_icon":0},{"id":"2481499981","title":"Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2481499981","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481499981?lang=en_us&edition=fundamental","pubTime":"2024-11-08 15:29","pubTimestamp":1731050962,"startTime":"0","endTime":"0","summary":"Revenue: $41.7 million for Q3 2024, down from $45.1 million in Q3 2023.Operating Expenses: $52.4 million for Q3 2024, compared to $64.5 million in Q3 2023.Research and Development Expenses: $39.1 million for Q3 2024, down from $51.1 million in Q3 2023.Net Loss: $6.9 million or $0.26 per diluted share for Q3 2024, compared to $16.2 million or $0.61 per diluted share for Q3 2023.Cash, Cash Equivalents, and Restricted Cash: $294.1 million as of September 30, 2024.Commercial Milestone: $25 million received with the first sale of KOSTAIVE in Japan.Cash Runway: Expected to extend into Q1 of fiscal year 2027.GuruFocus has detected 6 Warning Signs with ARCT.Arcturus Therapeutics Holdings Inc  successfully launched its COVID-19 vaccine, KOSTAIVE, in Japan, marking the company's first commercial product.Arcturus Therapeutics Holdings Inc  has a strong financial position with cash, cash equivalents, and restricted cash totaling $294.1 million as of September 30, 2024.Q: What can you share about t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/upodKMuOhkXOWA8.iNQo4Q--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5b2f73d677eb49c935ace64d2ab2be9e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/upodKMuOhkXOWA8.iNQo4Q--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5b2f73d677eb49c935ace64d2ab2be9e"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-holdings-inc-arct-072922848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT"],"gpt_icon":0},{"id":"2481916721","title":"Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481916721","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481916721?lang=en_us&edition=fundamental","pubTime":"2024-11-08 06:55","pubTimestamp":1731020108,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics  came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 62.86%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $1.85 per share when it actually produced a loss of $0.64, delivering a surprise of 65.41%.Arcturus Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $41.67 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 15.23%. This compares to year-ago revenues of $45.14 million. The company has topped consensus revenue estimates two times over the last four quarters.Arcturus Therapeutics shares have lost about 41.9% since the beginning of the year versus the S&P 500's gain of 24.3%.While Arcturus Therapeutics has underperformed the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-arct-reports-q3-225508197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARCT"],"gpt_icon":0},{"id":"2481258167","title":"Arcturus Therapeutics: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2481258167","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481258167?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:48","pubTimestamp":1731016103,"startTime":"0","endTime":"0","summary":"SAN DIEGO  — SAN DIEGO  — Arcturus Therapeutics  on Thursday reported a loss of $6.9 million in its third quarter.On a per-share basis, the San Diego-based company said it had a loss of 26 cents.The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 70 cents per share.The pharmaceutical company posted revenue of $41.7 million in the period, which fell short of Street forecasts. Four analysts surveyed by Zacks expected $49.2 million.Arcturus Therapeutics shares have declined 41% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $18.74, a fall of slightly more than 4% in the last 12 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-q3-earnings-snapshot-214823451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","ARCT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":-0.1005},{"period":"1month","weight":-0.0427},{"period":"3month","weight":-0.2489},{"period":"6month","weight":-0.4361},{"period":"1year","weight":-0.5051},{"period":"ytd","weight":-0.509}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.080132},{"month":2,"riseRate":0.545455,"avgChangeRate":0.011691},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.021161},{"month":4,"riseRate":0.545455,"avgChangeRate":0.101832},{"month":5,"riseRate":0.636364,"avgChangeRate":0.1056},{"month":6,"riseRate":0.583333,"avgChangeRate":0.023074},{"month":7,"riseRate":0.583333,"avgChangeRate":0.109538},{"month":8,"riseRate":0.5,"avgChangeRate":0.045801},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.063785},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.046065},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063018},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.068812}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction